Inauhzin is primarily researched for its potential in cancer therapy. It functions by inhibiting SIRT1, a protein involved in cellular regulation and stress responses. This inhibition leads to the activation of p53, a tumor suppressor protein, which can induce apoptosis in cancer cells. Studies suggest that Inauhzin may be effective in targeting various types of cancers, particularly those with p53 mutations. Its application is currently in the experimental stage, with ongoing research to determine its efficacy and safety in clinical settings. Additionally, it is being explored for its role in enhancing the effectiveness of other cancer treatments, such as chemotherapy and radiation, by sensitizing cancer cells to these therapies.